Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Activated vitamin D analogue for inhibiting appetite

An appetite and drug technology, applied in the direction of organic active ingredients, drug combinations, medical preparations containing active ingredients, etc., can solve problems such as abnormal liver function tests, elevated blood pressure, and impact on the health of users

Inactive Publication Date: 2016-04-06
CINKATE PHARM TECH SHANGHAI CO LTD +1
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the appetite-suppressing drugs sold on the market directly act on the central nervous system, so that people will not feel hungry even if they eat a little.
However, common appetite-suppressing drugs usually have obvious adverse reactions, which can lead to a series of side effects, such as dry mouth, anorexia, insomnia, constipation; fever; increased heart rate, increased blood pressure; bronchitis, dyspnea; diarrhea, gastroenteritis, Flatulence; restlessness, limb cramps, increased tension, abnormal thinking, seizures, interstitial nephritis, menstrual disturbances; skin ecchymosis due to prolonged bleeding; peripheral edema; arthritis; pruritus; amblyopia; liver function Check abnormalities, etc., which seriously affect the health of the user

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Activated vitamin D analogue for inhibiting appetite
  • Activated vitamin D analogue for inhibiting appetite
  • Activated vitamin D analogue for inhibiting appetite

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1CK15

[0063] Embodiment 1 CK15 rat administration experiment

[0064] After 28 days of administration of CK15, the food intake and body weight of the rats were reduced; after 28 days of recovery from drug withdrawal, the food intake and body weight returned to normal levels.

[0065] The purpose of the experiment: to explore whether CK15 can cause the reduction of food intake and body weight in rats

[0066] Test method: Male and female rats were randomly divided into four groups: control group, low dose group (0.5 μg / kg), middle dose group (5 μg / kg), high dose group (10 μg / kg). Administration was given once a day for 28 consecutive days, and the recovery period was 28 days, and the food intake and body weight of each group of animals were recorded, as well as clinical observations by the side of the cage. After the administration, some animals were dissected, and the remaining animals entered the recovery period.

[0067] test results:

[0068] (1) Changes in animal body weight:...

Embodiment 2CK15

[0106] Embodiment 2 CK15 dog administration experiment

[0107] The purpose of the experiment: To explore whether CK15 can cause a decrease in food intake and weight loss in dogs

[0108] Test method: Male and female dogs were randomly divided into four groups: control group, low dose group (0.5 μg / kg), medium dose group (2.5 μg / kg), high dose group (5 μg / kg). Administration was given once a day for 28 consecutive days, and the recovery period was 28 days, and the food intake and body weight of each group of animals were recorded, as well as clinical observations by the side of the cage. After the dosing period, some animals were dissected, and the remaining animals entered the recovery period.

[0109] test results:

[0110] (1) Changes in animal weight: as shown in Table 5

[0111] Table 5-1 Body weight change of female animals (kg)

[0112]

[0113] Note: n is the number of animals in each group; *, compared with 0μg / kg group, P<0.05;

[0114] #: recovery period 28 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an activated vitamin D analogue for inhibiting appetite. To be specific, the invention provides application of a compound which is as shown in the formula (I) and used for preparing a medicine composition for inhibiting animal appetite. The medicine composition has the advantages that no side effect or few side effects are generated to a user, in particular, hypercalcemia is not easy to cause, and the activated vitamin D analogue is quite suitable for being used for preparing appetite inhibiting medicine or weight-reducing medicine.

Description

technical field [0001] The invention relates to the field of pharmaceutical compounds, in particular, the invention provides an appetite-suppressing active vitamin D analogue. Background technique [0002] Obesity has increasingly become a major hidden danger to public health. How to lose weight is not only to pursue body shape, but more importantly, to be responsible for future health. Today's diet pills basically have two principles: one is to suppress appetite, and the other is to promote excretion. [0003] At present, the appetite-suppressing drugs sold on the market directly act on the central nervous system, so that people will not feel hungry even if they eat a little. . However, common appetite-suppressing drugs usually have obvious adverse reactions, which can lead to a series of side effects, such as dry mouth, anorexia, insomnia, constipation; fever; increased heart rate, increased blood pressure; bronchitis, dyspnea; diarrhea, gastroenteritis, Flatulence; re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/59A61P3/04
Inventor 肖飞贺利军刘荣军
Owner CINKATE PHARM TECH SHANGHAI CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com